Engitix raises £20m Series A extension from Netherton Investments to develop therapies for cancer and fibrosis

Engitix, a biotech company targeting the extracellular matrix (ECM) to develop transformative therapies for cancer and fibrosis, today announced the closing of a £20 million Series A extension financing, by Netherton Investments, a fund investing on behalf of Mike Platt, the co-founder and Managing Director of BlueCrest Capital Management.

Engitix leverages deep, high-resolution ECM data to identify disease-associated signatures and translate them into therapeutics designed to act precisely within diseased tissue microenvironments.

By building large, high-quality datasets from human tissue, the company identifies patterns linked to disease and uses insights to design more targeted therapies. This approach is intended to make early-stage drug development more accurate and relevant to patients, particularly in areas where existing treatments and models have struggled to deliver consistent results.

Proceeds will be used to continue preclinical development across Engitix’s proprietary ECM-targeted pipeline in solid tumors and fibrosis, and to further expand and apply Engitix’s platform built on one of the largest proprietary ECM datasets in these diseases.